drugset / Trial / NCT00529750

Effect of the Angiotensin II Receptor Antagonist Irbesartan on Biochemical and Functional Markers of Endothelial Dysfunction in Patients With Hypertension

NCT00529750

Phase 4 Completed 108 enrolled Sanofi
RandomizedParallel-groupDouble-blindTreatment

Summary

Primary: * To evaluate the impact of irbesartan on endothelial function in hypertensive patients with metabolic syndrome. Secondary: * To evaluate the oxidative stress status in patients with hypertension with metabolic syndrome. * To correlate the oxidative stress status with endothelial function in these patients. * To evaluate the effect of irbesartan on the oxidative stress stage in patients with metabolic syndrome and to correlate it with the effect on endothelial function . * To correlate the change in endothelial function and oxidative stress stage with the change of arterial pressure levels.

Timeline

Start
2002-07
Primary completion
2005-01
Completion
2005-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atenolol Other / unclassified 50 mg Oral
Subject Irbesartan Small molecule 150 mg Oral

Indications